22423-26-3
基本信息
2,2'-脱水胸苷
2,2'-anhydro-1-beta-arabinofuranosylthymine
2,2'-ANHYDRO-(1-BETA-D-ARABINOFURANOSYL)THYMINE
2,2'-ANHYDRO-(1-E-D-ARABINOFURANOSYL)-5-METHYLURACIL
2,2'-ANHYDRO-5-METHYLURIDINE
2,2'-ANHYDROTHYMIDINE
(2r-(2alpha,3beta,3abeta,9abeta))-2,3,3a,9a-tetrahydro-3-hydroxy-2-(hydroxymethyl)-7-methyl-6h-furo(2',3':4,5)oxazolo(3,2-a)pyrimidin-6-one
6H-FURO[2',3':4,5]OXAZOLO[3,2-A]PYRIMIDIN-6-ONE,2,3,3A,9A-TETRAHYDRO-3-HYDROXY-2-(HYDROXYMETHYL)-7-METHYL-, (2R,3R,3AS, 9AR)-
2,2'-cyclo-5-methyluridine
2,2'-Anhydrothimidine
Uridine,2,2'-cyclo-5-methyl
2,2'-Anhydro-D-thymidine
2,2’-Cryclo-5-methyluridine
2,2''-Anhydro-(1-beta-D-arabinofuranosyl)-5-methyluracil
6H-Furo[2'',3'':4,5]oxazolo[3,2-a]pyrimidin-6-one, 2,3,3a,9a-tetrahydro-3-hydroxy-2-(hydroxymethyl)-7-methyl-, (2R,3R,3aS, 9aR)-
(2R-(2alpha,3beta,3abeta,9abeta))-2,3,3a,9a-Tetrahydro-3-hydroxy-2-(hydroxymethyl)-7-methyl-6H-furo(2',3':4,5)oxazolo(3,2-a)pyrimidin-6-one
(2R)-2,3,3aβ,9aβ-Tetrahydro-3β-hydroxy-2α-(hydroxymethyl)-7-methyl-6H-furo[2',3':4,5]oxazolo[3,2-a]pyrimidin-6-one
(8R,10R,11R,12S)-5-Methyl-10-(hydroxymethyl)-11-hydroxy-2,7:8,12-dicyclo-1,9-dioxa-3,7-diazacyclododeca-2,5-diene-4-one
2,2'β-Oxy-2-deoxo-2,3-didehydro-2'-deoxy-5-methyluridine
2'β,2-Epoxy-2,3-didehydro-2-deoxothymidine
物理化学性质
| 外观性状 | 2,2'-脱水-5-甲基尿苷(22423-26-3)为白色或白色结晶粉末 |
| 熔点 | 217.0 to 221.0 °C |
| 沸点 | 452.0±55.0 °C(Predicted) |
| 密度 | 1.88±0.1 g/cm3(Predicted) |
| 储存条件 | Sealed in dry,Room Temperature |
| 水溶解性 | 溶于水 |
| 酸度系数(pKa) | 12.56±0.60(Predicted) |
| 形态 | 粉末晶体 |
| 颜色 | 白色到近乎白色 |
| InChI | InChI=1S/C10H12N2O5/c1-4-2-12-9-7(6(14)5(3-13)16-9)17-10(12)11-8(4)15/h2,5-7,9,13-14H,3H2,1H3/t5-,6-,7+,9-/m1/s1 |
| InChIKey | WLLOAUCNUMYOQI-JAGXHNFQSA-N |
| SMILES | C12O[C@@]3([H])[C@H](O)[C@@H](CO)O[C@@]3([H])N1C=C(C)C(=O)N=2 |
| CAS 数据库 | 22423-26-3(CAS DataBase Reference) |
安全数据
| 危险性符号(GHS) | ![]() GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
| 海关编码 | 2940.00.6000 |
制备方法
1463-10-1
22423-26-3
以下为以5-甲基尿苷为原料合成(2R,3R,3aS,9aR)-3-羟基-2-(羟甲基)-7-甲基-2,3,3a,9a-四氢-6H-呋喃[2',3':4,5]恶唑并[3,2-a]嘧啶-6-酮的一般步骤: 1. 在碳酸二苯酯和NaHCO3催化下,于100℃在DMF中进行反应,产率90%。 2. 使用DMTCl在吡啶中室温反应,产率89%。 3. 在乙二醇、Ti(OiPr)4和NaHCO3催化下,于THF中150℃反应,产率79%。 4. 以MsCl和Et3N在DCM中进行反应,产率57%。 5. 使用NaN3和18-冠-6在DMF中反应,产率89%。 6. 以Ph3P和H2O在THF中反应,产率89%。 7. 在DCM和Et3N中反应,产率88%。 8. 最后,使用(iPr)2NP(Cl)OCH2CH2CN和DIPEA在DCM中室温反应,产率59.4%。
参考文献:
[1] Patent: CN103450302, 2016, B. Location in patent: Paragraph 0096-0098; 0110
[2] Patent: US2013/231473, 2013, A1. Location in patent: Paragraph 0158
[3] Patent: US2005/107324, 2005, A1. Location in patent: Page/Page column 26
[4] Journal of the Brazilian Chemical Society, 2015, vol. 26, # 4, p. 816 - 821
[5] Bioorganic and Medicinal Chemistry, 2005, vol. 13, # 5, p. 1641 - 1652
